Skip to NavigationSkip to content

Top 50 Selling Products in the World by 2022

Published on 06/07/17 at 05:07pm

This article was originally published in Pharmafile Spring 2017.

Opdivo and Revlimid to compete for the top spot in 2022, while Humira is expected to step down following biosimilar launch.

EvaluatePharma sellside consensus forecast finds that Opdivo, Bristol-Myers Squibb’s anti-PD-1 monoclonal antibody, will be the number one selling product worldwide in 2022, with sales of $14.6bn.

However, following the recent setback in non-small cell lung cancer (NSCLC), Revlimid could take the crown with expected sales of $13bn in 2022 provided that Humira loses ground following the potential launch of biosimilars (current forecast still positions Humira at number two with $13.6bn in 2022).

In the PD-1 gold rush, Merck’s Keytruda – currently anticipated to reach close to $6bn in 2022 – is expected to take advantage of Opdivo’s recent setback in NSCLC, while Roche’s Tecentriq is expected to reach $5.3bn in 2022.

Only three products currently in R&D are present in the top 50, the biggest of which is Roche’s Ocrevus, a phase 3 anti-CD20 MAb for the treatment of multiple sclerosis. It is expected to launch worldwide in December 2017.

 

The top 50 best-selling drug products:

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches